Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling with topical minoxidil is effective for hair regrowth, especially with finasteride. Users report fewer side effects compared to oral minoxidil.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user shared a 4-month update on their hair regrowth journey using finasteride, minoxidil, and microneedling, reporting significant progress and styling ability. They emphasized persistence, shared their regimen details, and addressed side effects like weaker erections and blurry vision, which improved with lifestyle changes.

A user shared their 3-month experience with oral Minoxidil and nearly a year on finasteride, asking if a hair transplant might still be needed. Responses varied from congratulatory remarks on visible improvement to advice on sticking with treatments despite initial shedding.

Genetics mainly cause hair loss, but diet, stress, smoking, and alcohol can worsen it. Treatments include finasteride, minoxidil, and lifestyle changes like a healthy diet and avoiding caffeine.

A user shared their hormone levels to gauge if they can use finasteride for hair loss without issues. Their hormone levels are mostly within the reference ranges.

User shares 1-month vs 9-month finasteride results for hair loss. Commenters discuss photo angles, hair regrowth, and side effects.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

Hair loss in a 3-year-old, with various treatments discussed such as minoxidil, finasteride, dutasteride, RU58841 and biotin supplementation. Some people suggested shaving the head and growing a beard or getting a partial hairpiece instead of attempting to treat it.

User shared 12-month hair growth progress using finasteride and dutasteride, with nizoral 3x per week. They experienced a finasteride shed but saw improvement after a year and offered advice for managing hair loss expectations.

A 22-year-old is experiencing hair thinning despite using finasteride and dutasteride, and plans to try minoxidil next. The user is frustrated with the lack of results and is considering drastic measures if the situation doesn't improve.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

The conversation discusses hair thinning and treatments like Minoxidil, finasteride, and RU58841. The user is concerned about distinguishing between natural hair parting and actual thinning.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses whether a longtime NW7 scalp has vellus hairs under a microscope or is completely smooth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user is likely at Norwood level 3 with thinning at the crown and temple recession. Treatments like finasteride or minoxidil are suggested to manage hair loss.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The user is experiencing rapid hair loss, progressing from Norwood 3 to 7, with thinning at the crown and receding hairline. Suggested treatments include finasteride, minoxidil, ketoconazole shampoo, and CBD with MCT oil.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

A user ordered H&W's 1.25% Topical Finasteride and is curious about others' experiences and side effects. Another user asked about availability in the US.

A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

The user is considering using topical finasteride for thinning hair around the middle part, vertex, and crown, and is unsure if the whole scalp is thinning. Another user suggests oral finasteride is more effective than topical, and recommends consulting a dermatologist for proper treatment.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

A user maintains NW2 hair with 1mg finasteride, 2.5mg oral minoxidil, and 5% topical minoxidil twice daily, along with ketoconazole shampoo and derma stamping. They seek advice on more aggressive treatments to achieve NW1.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.